ibuprofenamine
Phase 3- Indications
- Osteoarthritis
Company intelligence / Profile preview
XinChen-Techfields Pharma
Princeton, New Jersey, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Lead product X0002 (Ibuprofenamine Hydrochloride) is in Phase 3 clinical trials for knee osteoarthritis pain with Fast Track designation from FDA. Preclinical studies showed potential for 98.5% reduction in required dose compared to oral administration, with 100X greater tissue penetration.
- Therapeutic areas
- Men's HealthEndocrinologyPsychiatryRheumatologyNeurologyInfectious Diseases
- Modalities
- Small molecule drugsChemical drugsProdrugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on XinChen-Techfields Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XinChen-Techfields Pharma.